Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

COVID19

CDC Reverses Course on Masks for Fully Vaccinated in Light of SARS-CoV-2 Variants

Diana Ernst, RPh

July 30, 2021

The CDC also issued a health advisory about the urgent need to increase COVID-19 vaccination coverage.

Urinary Tract Infections

FDA Needs More Data on Sulopenem for Uncomplicated UTI

Diana Ernst, RPh

July 29, 2021

The NDA submission was supported by data from the phase 3 SURE1 clinical trial.

General Infectious Disease

Single-Dose Solosec Approved for Trichomoniasis

Diana Ernst, RPh

July 7, 2021

Since trichomoniasis is a sexually transmitted disease, sexual partners should be treated with the same dose and at the same time.

Respiratory

FDA Approves 20-Valent Pneumococcal Conjugate Vaccine Prevnar 20

Diana Ernst, RPh

June 11, 2021

The vaccine contains capsular polysaccharide conjugates for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) that cause invasive pneumococcal disease.

News, Sexually Transmitted Diseases

FDA Clears Point-of-Care Test for Chlamydia, Gonorrhea

Diana Ernst, RPh

April 6, 2021

The io instrument processes a single-use cartridge that contains all reagents for testing collected vaginal swabs and male urine samples.

COVID19

Pediatric Trial Evaluating Moderna’s COVID-19 Vaccine Begins

Diana Ernst, RPh

March 19, 2021

The phase 2/3 KidCOVE study [ClinicalTrials.gov: NCT04796896] is evaluating the safety and effectiveness of the vaccine in healthy children between 6 months and less than 12 years of age.

COVID19

Study Findings Do Not Support Use of Ivermectin for Mild COVID-19

Diana Ernst, RPh

March 15, 2021

The median time to resolution of COVID-19 symptoms was 10 days with ivermectin and 12 days with placebo.

COVID19

CDC Provides Guidance for Individuals Fully Vaccinated Against COVID-19

Diana Ernst, RPh

March 9, 2021

Fully vaccinated individuals can visit with other fully vaccinated people, or unvaccinated people from a single household who are at low risk for severe COVID-19 disease, indoors without wearing masks or physical distancing.